Three independent discounted-cash-flow-style models value Summit Therapeutics Inc. Common Stock every trading day. 0 of 3 currently price SMMT above its market price.
| Free Cash Flow model | $-0.49 |
| Excess Profit model | $0.16 |
| Residual Earnings model | $-0.02 |
| Dividend Discount model | — |
| Piotroski F-Score | 3 / 9 |
| Return on invested capital | -56.2% |
| Net debt / EBITDA | — |
| Gross margin | +100.0% |
| Revenue CAGR | -44.3% |
| Cash conversion | — |
| Dividend yield | — |
| Buyback yield | -16.0% |
These are StockKitty's default assumptions. In the app, the models recompute live as you adjust growth, discount rates, and margins — and the AI explains the bull case, bear case, and quality picture.
Open SMMT in StockKitty